News

Summit to Present Additional Data from Phase 2 CoDIFy Trial for the Tr


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Summit to Present Additional Data from Phase 2 CoDIFy Trial for the Treatment of C. Difficile Infection


29/03/2016

Oxford, UK – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy andth abstract 

Rates of clinical cure at the end of treatment in the Phase 2 CoDIFy trial were 77.8% for ridinilazole and 69.7% for vancomycin. These analyses were conducted on the modified intent-to-treat (‘mITT’) population that comprised subjects with CDI diagnosed by the presence of free toxin in faeces.

The related poster, entitled “Ridinilazole for


CompanySummit Therapeutics plc
Company Websitehttp://www.summitplc.com/
 

© Catalyst Innovation Portal 2019